Magazine Article | March 5, 2019

The Unique Demands of Cell and Gene Therapy Supply Chains

Source: Cell & Gene

By Erin Harris, editor-in-chief

Innovations in the cell and gene sector continue to advance development of safe and effective therapies. But can the cell and gene therapy sector’s exceptionally complex supply chains keep up with the rapid rate of progress? I conferred with three of the field’s most valuable luminaries representing both academia and industry — Dr. Bruce Levine, Barbara and Edward Netter professor in Cancer Gene Therapy at the University of Pennsylvania; Simon Ellison, ISCT (International Society of Cell & Gene Therapy) Commercialization Committee; and Ryan Bartock, head of supply chain and network strategy at Spark Therapeutics — to determine how CMOs can and should successfully manage cell and gene therapy supply chains.